Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.62 |
| ▸ | MAPT | P10636 | 2/20 | 0.62 |
| ▸ | AHR | P35869 | 1/20 | 0.62 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | HTR2A | P28223 | 5/20 | 0.55 |
| ▸ | HTR2C | P28335 | 3/20 | 0.55 |
| ▸ | HTR6 | P50406 | 3/20 | 0.55 |
| ▸ | HTR1D | P28221 | 2/20 | 0.55 |
| ▸ | HTR1B | P28222 | 2/20 | 0.55 |
| ▸ | HTR7 | P34969 | 2/20 | 0.55 |
| ▸ | MPO | P05164 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22879441 | 0.85 | MEN1 (0.58) | MEN1KMT2ACYP3A4MAPTAHR | |
| SCHEMBL8699685 | 0.85 | MEN1 (0.58) | MEN1KMT2ACYP3A4MAPTAHR | |
| SCHEMBL4100216 | 0.85 | MEN1 (0.58) | MEN1KMT2ACYP3A4MAPTAHR | |
| SCHEMBL30354035 | 0.85 | MEN1 (0.58) | MEN1KMT2ACYP3A4MAPTAHR | |
| SCHEMBL9794857 | 0.85 | MEN1 (0.58) | MEN1KMT2ACYP3A4MAPTAHR | |
| SCHEMBL27452680 | 0.85 | MEN1 (0.58) | MEN1KMT2ACYP3A4MAPTAHR | |
| Hydrochloric Acid SCHEMBL27797436 | 0.84 | PMP22 (0.57) | MEN1KMT2ACYP3A4MAPTAHR | |
| SCHEMBL12413778 | 0.84 | MEN1 (0.56) | MEN1KMT2ACYP3A4MAPTAHR | |
| SCHEMBL10145510 | 0.82 | MEN1 (0.59) | MEN1KMT2ACYP3A4MAPTAHR | |
| SCHEMBL19134737 | 0.82 | MEN1 (0.55) | MEN1KMT2ACYP3A4MAPTAHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 312 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037415-B2 | Peptide and pharmaceutical composition for treating an eye disease comprising the same as an active pharmaceutical ingredient | YUYU PHARMA, INC. (KR) | 2024-07-16 | — | — | US | disclosed |
| US-20240226320-A1 | DRUG CONJUGATES WITH SELF-STABILIZING LINKERS HAVING IMPROVED PHYSIOCHEMICAL PROPERTIES | SEAGEN INC (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240226320-A1 | DRUG CONJUGATES WITH SELF-STABILIZING LINKERS HAVING IMPROVED PHYSIOCHEMICAL PROPERTIES | SEAGEN INC (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240216420-A1 | HYDROPHOBIC AURISTATIN F COMPOUNDS AND CONJUGATES THEREOF | SEAGEN INC (US) | 2024-07-04 | — | — | US | disclosed |
| US-20240216420-A1 | HYDROPHOBIC AURISTATIN F COMPOUNDS AND CONJUGATES THEREOF | SEAGEN INC (US) | 2024-07-04 | — | — | US | disclosed |
| US-20240016953-A1 | TARGETED DELIVERY OF NICOTINAMINDE ADENINE DINUCLEOTIDE SALVAGE PATHWAY INHIBITORS | SEAGEN INC (US) | 2024-01-18 | — | — | US | disclosed |
| US-20240016953-A1 | TARGETED DELIVERY OF NICOTINAMINDE ADENINE DINUCLEOTIDE SALVAGE PATHWAY INHIBITORS | SEAGEN INC (US) | 2024-01-18 | — | — | US | disclosed |
| US-11859242-B2 | Template-directed nucleic acid targeting compounds | CARNEGIE MELLON UNIVERSITY (US) | 2024-01-02 | — | — | US | disclosed |
| US-11857565-B2 | Hydrophobic Auristatin F compounds and conjugates thereof | SEAGEN INC. (US) | 2024-01-02 | — | — | US | disclosed |
| US-11857565-B2 | Hydrophobic Auristatin F compounds and conjugates thereof | SEAGEN INC. (US) | 2024-01-02 | — | — | US | disclosed |
| EP-1495009-B1 | CYANAMIDES USEFUL AS REVERSIBLE INHIBITORS OF CYSTEINE PROTEASES | BOEHRINGER INGELHEIM PHARMA (US) | 2008-03-12 | — | — | EP | disclosed |
| US-20080051326-A1 | Antiinfective Lipopeptides | CUBIST PHARMACEUTICALS, INC. | 2008-02-28 | — | — | US | disclosed |
| US-20080051326-A1 | Antiinfective Lipopeptides | CUBIST PHARMACEUTICALS, INC. | 2008-02-28 | — | — | US | disclosed |
| US-7291744-B2 | N-ureidoalkyl-amino compounds as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-11-06 | — | — | US | disclosed |
| US-20070185115-A1 | Novel ureido-and amido-pyrazolone derivatives | ASTON UNIVERSITY (GB) | 2007-08-09 | — | — | US | disclosed |
| US-20070155730-A1 | Benzodiazepine And Benzopiperazine Analog Inhibitors Of Histone Deacetylase | METHYLGENE, INC. (CA) | 2007-07-05 | — | — | US | disclosed |
| US-20070155730-A1 | Benzodiazepine And Benzopiperazine Analog Inhibitors Of Histone Deacetylase | METHYLGENE, INC. (CA) | 2007-07-05 | — | — | US | disclosed |
| US-20070042988-A1 | Antiviral phosphoramidates | ROCHE PALO ALTO LLC | 2007-02-22 | — | — | US | disclosed |
| US-20070021331-A1 | Methods of using macrocyclic modulators of the ghrelin receptor | TRANZYME PHARMA INC. | 2007-01-25 | — | — | US | disclosed |
| US-4508725-A | BETA-ADRENERGIC BLOCKING AGENTS; GLAUCOMA TREATMENT | AMERICAN HOSPITAL SUPPLY CORPORATION (US) | 1985-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185115-A1 | Novel ureido-and amido-pyrazolone derivatives | CCKAR, CCKBR, GRPR | MEN1 3287/4885KMT2A 4491/4885CYP3A4 1582/4885 |
| US-20070042988-A1 | Antiviral phosphoramidates | RPP30, RNASE1, ADORA2B | MEN1 3374/4885KMT2A 2828/4885CYP3A4 2407/4885 |
| US-20240016953-A1 | TARGETED DELIVERY OF NICOTINAMINDE ADENINE DINUCLEOTIDE SALVAGE PATHWAY INHIBITORS | NAMPT, NAPRT, NNMT | MEN1 749/4885KMT2A 2535/4885CYP3A4 4861/4885 |
| US-20240226320-A1 | DRUG CONJUGATES WITH SELF-STABILIZING LINKERS HAVING IMPROVED PHYSIOCHEMICAL PROPERTIES | CD44, CD47, UACA | MEN1 397/4885KMT2A 1837/4885CYP3A4 3782/4885 |
| US-11857565-B2 | Hydrophobic Auristatin F compounds and conjugates thereof | MSN, AURKA, AURKC | MEN1 948/4885KMT2A 1577/4885CYP3A4 3276/4885 |
| US-20080051326-A1 | Antiinfective Lipopeptides | VIP, NGLY1, PREP | MEN1 2623/4885KMT2A 4448/4885CYP3A4 4531/4885 |
| US-12037415-B2 | Peptide and pharmaceutical composition for treating an eye disease comprising the same as an active pharmaceutical ingredient | VIP, IAPP, NGLY1 | MEN1 1538/4885KMT2A 4846/4885CYP3A4 4834/4885 |
| US-20240216420-A1 | HYDROPHOBIC AURISTATIN F COMPOUNDS AND CONJUGATES THEREOF | MSN, AURKA, AURKC | MEN1 948/4885KMT2A 1577/4885CYP3A4 3276/4885 |
| US-20070021331-A1 | Methods of using macrocyclic modulators of the ghrelin receptor | GHSR, GHRHR, GIPR | MEN1 982/4885KMT2A 2083/4885CYP3A4 2981/4885 |
| US-20070155730-A1 | Benzodiazepine And Benzopiperazine Analog Inhibitors Of Histone Deacetylase | HDAC5, HDAC4, HDAC3 | MEN1 4013/4885KMT2A 111/4885CYP3A4 395/4885 |
| US-11859242-B2 | Template-directed nucleic acid targeting compounds | TARDBP, HTT, TRDMT1 | MEN1 1494/4885KMT2A 846/4885CYP3A4 4801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.